Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18

Author:

Leighl Natasha B.1,Paz-Ares Luis1,Douillard Jean-Yves1,Peschel Christian1,Arnold Andrew1,Depierre Alain1,Santoro Armando1,Betticher Daniel C.1,Gatzemeier Ulrich1,Jassem Jacek1,Crawford Jeffrey1,Tu Dongsheng1,Bezjak Andrea1,Humphrey Jeffrey S.1,Voi Maurizio1,Galbraith Susan1,Hann Katherine1,Seymour Lesley1,Shepherd Frances A.1

Affiliation:

1. From the National Cancer Institute of Canada–Clinical Trials Group, Kingston; University Health Network/Princess Margaret Hospital, Toronto; The Margaret & Charles Juravinski Cancer Centre (formerly known as Hamilton Regional Cancer Centre), Hamilton, Ontario; Hospital Universitario Doce de Octubre, Madrid, Spain; Centre Rene Gauducheau, Nantes, France; Klinikum Rechts Der III Medizinische Klinik, Munich; Krankenhaus Grobhansdorf der LVA, Grobhansdorf, Germany; Hôpital Jean Minjoz, Besançon, France;...

Abstract

Purpose To determine whether BMS-275291, a broad-spectrum matrix metalloproteinase inhibitor (MMPI), added to systemic chemotherapy improved survival in advanced non–small-cell lung cancer (NSCLC). In early phase studies, BMS- 275291 was not associated with dose-limiting joint toxicity seen with other MMPIs. Patients and Methods Chemotherapy-naive patients with stage IIIB/IV NSCLC, performance status (PS) 0 to 2, and adequate organ function were eligible. All patients received paclitaxel 200 mg/m2 plus carboplatin (area under the curve, 6 mg/mL-min) intravenously every 21 days for up to 8 cycles, and were randomly assigned to receive BMS-275291, 1,200 mg orally daily, or placebo until disease progression. The primary study end point was survival (OS); secondary end points included progression-free survival (PFS), response rates (RR), toxicity, and quality of life. Results From 2000 to 2002, 774 patients were randomly assigned. Pretreatment characteristics were well balanced between arms: median age, 61 years; male sex, 73%; stage IV, 79%; PS 0 to 1, 88%. Interim safety analysis revealed no survival advantage and increased toxicity in the experimental arm, and study treatment was stopped. Median OS, PFS and RR in the final analysis in the BMS-275291 arm were 8.6 months, 4.9 months, and 25.8% respectively, and in the control arm 9.2 months, 5.3 months, 33.7%. Toxicity was significantly higher in the BMS-275291 arm, including flu-like symptoms, rash, hypersensitivity reactions (8.6% v 2.4%), and febrile neutropenia (9.7% v 5.5%). Conclusion BMS-275291 added to chemotherapy increases toxicity and does not improve survival in advanced NSCLC.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Reference22 articles.

1. Estimating the world cancer burden: Globocan 2000

2. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy for non-small cell lung cancer [Cochrane Database System Review] . Oxford, England, Cochrane Library, CD002139, issue 2, 2000

3. Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

4. Janecki-Delebecq T, Porte H, Zerimech F, et al: Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer. Clin Cancer Res 6:1086,2000-1092,

Cited by 164 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3